Skip to content
Screener

Arcus Biosciences RCUS Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$33.0MMiss by $2.7M
EPS-$0.89Beat by $0.22
Revenue estimate$35.7M
EPS estimate-$1.11

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q4 2025

Income statement

See full
Revenue$33.0M+26.9%
Operating income-$114.0M-10.7%
Net income-$106.0M-12.8%
EPS (diluted)-$0.90+12.6%

Balance sheet

See full
Cash & equivalents$222.0M+48.0%
Total debt$198.0M+24.5%
Total equity$631.0M+30.1%
Total assets$1.1B-1.0%

Cash flow

See full
Operating cash flow-$120.0M-20.0%
CapEx$1.0M0.0%
Free cash flow-$121.0M-19.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.95B+116%
Enterprise value$2.92B+113%
P/S11.9×+6.7×

Profitability

See full
Operating margin-156.3%+44.5pp
Net margin-142.9%+62.1pp
FCF margin-196%—

Returns & leverage

See full
Return on equity-63.3%+3.9pp
Debt / equity0.3×0.0×
Current ratio4.4×-0.1×

Segments

By segment

See full
Reportable segment$33.0M+26.9%

FAQ

When did Arcus Biosciences report Q4 2025 earnings?
Arcus Biosciences (RCUS) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Arcus Biosciences's Q4 2025 revenue and EPS?
Arcus Biosciences reported revenue of $33.0M and eps of $-0.89 for Q4 2025.
Did Arcus Biosciences beat estimates in Q4 2025?
Revenue missed the consensus estimate of $35.7M by $2.7M. EPS beat the consensus estimate of $-1.11 by $0.22.
How did Arcus Biosciences's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 26.9% from $26.0M a year earlier and eps grew 13.6% from $-1.03.
Where can I find Arcus Biosciences's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001724521-26-000007) and the 10-K periodic report (0001724521-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.